Point72 Asia Singapore Pte. Ltd. Buys New Stake in Personalis, Inc. (NASDAQ:PSNL)

Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,880 shares of the company’s stock, valued at approximately $28,000.

Other institutional investors also recently bought and sold shares of the company. abrdn plc purchased a new position in Personalis during the fourth quarter valued at $1,722,000. Dimensional Fund Advisors LP grew its stake in Personalis by 144.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after acquiring an additional 242,141 shares in the last quarter. Barclays PLC grew its stake in Personalis by 67.1% during the fourth quarter. Barclays PLC now owns 109,368 shares of the company’s stock valued at $632,000 after acquiring an additional 43,900 shares in the last quarter. Jane Street Group LLC grew its stake in Personalis by 144.3% during the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock valued at $2,320,000 after acquiring an additional 237,033 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Personalis in the 4th quarter worth $64,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PSNL has been the subject of a number of recent research reports. Guggenheim initiated coverage on shares of Personalis in a research note on Thursday, May 15th. They issued a “buy” rating and a $6.00 price objective for the company. Craig Hallum initiated coverage on shares of Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 price objective for the company. HC Wainwright lifted their price objective on shares of Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $7.67.

Personalis Trading Up 1.4%

Personalis stock opened at $5.02 on Tuesday. The firm has a 50-day moving average price of $3.79 and a 200-day moving average price of $4.45. The firm has a market capitalization of $443.39 million, a PE ratio of -2.99 and a beta of 1.83. Personalis, Inc. has a 12-month low of $1.14 and a 12-month high of $7.20.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. As a group, sell-side analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.